At CTAD, investigational Phase 1 drugs include a repackaged and a new anti-amyloid, a tau vaccine, and a repurposed cancer drug.
At CTAD, a handful of candidate therapies were reported to have flamed out in Phase 2. They were unable to show efficacy. A new antipsychotic is entering the ring.
Several therapeutic approaches in Phase 3 reported updates at the CTAD conference earlier this month in Barcelona. Read about levetiracetam, deep brain stimulation, and scyllo-inositol.
The CTAD conference featured discussion among many scientists of how to measure a drug’s effect in pre-dementia patients who are so mildly impaired that established tools have trouble picking up improvement. Better cognitive tools are needed.
Gantenerumab, Aducanumab: Bobbing Up and Down While Navigating Currents of Trial Design Outcomes, Outcomes: Cognition is Crux of New Alzheimer’s Trials Truly New to Déjà Vu: Investigational Therapy News at CTAD Truly New to Déjà Vu: For Five Hopefuls, ...
Both antibodies might be working, experts say, but the latest data released at the CTAD conference remain tantalizingly unclear. Trialists urgently need progression predictors and better outcome measures.
In a process known as repeat-associated non-ATG translation, neurons and glia make alanine, serine, cysteine, and leucine chains from the huntingtin gene.
Researchers report that an asparagine endopeptidase snips APP and promotes amyloid formation. They tout the protease as a therapeutic target.
Without the E3 ubiquitin ligase Idol, microglia readily gobble up ApoE and Aβ in a mouse model of Alzheimer’s disease.
Paralyzed mice recovered grip strength and balance when researchers turned off TDP-43.
Meet RBM45. This RNA-binding protein and relatively new player in the ALS field associates with stress-induced structures in the cytoplasm and nucleus.
A philanthropic organization has donated $177 million to train thought leaders from developing nations in dementia care and prevention.
Scientists say treatments to muzzle faulty genes are making some headway.
Researchers propose the same phenomenon explains poor clinical trial results.
John Hardy wins the Breakthrough Prize for his seminal research into the genetic underpinnings of Alzheimer’s disease.